FDA Expands Wegovy Approval to Reduce Cardiovascular Risk

A Landmark Moment for Obesity Treatment

In March 2024, the U.S. Food and Drug Administration expanded the approved uses of semaglutide 2.4 mg (Wegovy, Novo Nordisk) to include reducing the risk of serious cardiovascular events — specifically heart attack, stroke, and cardiovascular death — in adults with obesity or overweight who also have established cardiovascular disease. This made Wegovy the first weight-loss medication in history to receive such an indication, a milestone that obesity medicine specialists had long anticipated.

Prior to this approval, Wegovy was already indicated for chronic weight management in adults with a body mass index (BMI) of 30 or greater, or 27 or greater with at least one weight-related condition. The cardiovascular indication is a separate, additional layer — one that significantly broadens the clinical and insurance rationale for prescribing the drug. For the first time, a prescriber can justify Wegovy not just for weight reduction, but as an active intervention against life-threatening cardiac events.

The move also sends a signal to the broader medical community that semaglutide — and by extension the GLP-1 receptor agonist class — should be considered a cardiovascular drug, not merely a weight-loss drug. This framing is likely to shape how cardiologists, internists, and primary care physicians approach prescribing decisions for high-risk patients going forward.

What the SELECT Trial Showed

The new indication was built on data from the SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity) trial, a large-scale, randomized, double-blind, placebo-controlled cardiovascular outcomes trial. SELECT enrolled 17,604 adults aged 45 or older with overweight or obesity and pre-existing cardiovascular disease, but without diabetes. Participants were randomized to receive either weekly subcutaneous semaglutide 2.4 mg or placebo, in addition to standard care.

Over a mean follow-up period of approximately 34 months, those in the semaglutide group experienced a 20% reduction in the primary composite endpoint — a major adverse cardiovascular event (MACE) defined as death from cardiovascular causes, non-fatal myocardial infarction (heart attack), or non-fatal stroke. This 20% relative risk reduction was statistically significant and clinically meaningful, and it held across key subgroups regardless of sex, age, or degree of weight loss achieved.

Notably, the cardiovascular benefit appeared to begin accruing relatively early in the trial, within the first few months of treatment. Researchers noted that the magnitude of the benefit was not directly proportional to the amount of weight lost, suggesting that mechanisms beyond weight reduction — such as anti-inflammatory effects, improvements in lipid profiles, and direct cardiac receptor activity — may be contributing to the cardiovascular protection observed.

The SELECT trial results were published simultaneously in the New England Journal of Medicine and presented at the American Heart Association's Scientific Sessions in November 2023, generating significant attention from both the cardiology and endocrinology communities. The strength of the evidence was described by many experts as among the most compelling seen for any pharmacological weight-management intervention to date.

Who Is Eligible Under the New Approval?

The cardiovascular risk reduction indication specifically applies to adults with established cardiovascular disease and either obesity (BMI ≥ 30) or overweight (BMI ≥ 27). Established cardiovascular disease in this context refers to a prior history of heart attack, stroke, or symptomatic peripheral artery disease — conditions that place individuals at high risk for future events.

It is important to note that this indication does not extend to individuals who have only risk factors for cardiovascular disease (such as hypertension or elevated cholesterol) without a confirmed prior event. However, many patients who qualify under the original weight-management indication will also meet the criteria for the cardiovascular indication if they have relevant cardiac history — and having both indications may strengthen the case for insurance approval.

Patients with type 2 diabetes are not included in this specific indication (the SELECT trial excluded them), though semaglutide in its lower-dose form (Ozempic) has its own separate cardiovascular indication in patients with type 2 diabetes through the SUSTAIN-6 trial. Always consult your healthcare provider to determine which indication and which formulation is most appropriate for your individual medical profile.

What This Means for Insurance Coverage

One of the most practical consequences of the expanded approval is its potential impact on insurance coverage. Many insurance plans — including a significant number of commercial plans and Medicare Part D plans — have historically excluded weight-loss medications from their formularies, citing them as “lifestyle drugs” rather than medically necessary treatments. The cardiovascular indication changes this calculus in a meaningful way.

Because the drug is now formally approved to prevent heart attacks and strokes — conditions that insurance companies are explicitly required to cover treatment for — many plans may face legal and regulatory pressure to include Wegovy on their formularies, at least for patients who meet the cardiovascular criteria. Some plans have already updated their policies in response to this approval, and the trend is expected to continue.

For Medicare patients specifically, the SELECT data paved the way for CMS (Centers for Medicare & Medicaid Services) to consider coverage through the Inflation Reduction Act provisions. In 2025, CMS announced proposed rules that would allow Medicare Part D to cover anti-obesity medications for eligible patients, a policy shift directly influenced by the cardiovascular outcomes data. Patients who previously received denials may wish to file new appeals citing the expanded indication and any updated insurer guidelines.

Implications for GLP-1 Treatment Broadly

The Wegovy cardiovascular approval is not an isolated event — it is part of a broader pattern of GLP-1 receptor agonists demonstrating organ-protective benefits well beyond glucose control or weight reduction. Similar cardiovascular outcomes data exist for liraglutide (LEADER trial) and semaglutide 0.5/1 mg (SUSTAIN-6), and mounting evidence from the SURMOUNT and SURPASS programs suggests tirzepatide may follow a similar trajectory.

Researchers are now investigating GLP-1 effects on kidney disease, heart failure with preserved ejection fraction, non-alcoholic steatohepatitis (NASH), and Alzheimer's disease, among other conditions. The SELECT approval reinforces the hypothesis that these drugs act on multiple physiological pathways simultaneously, and that their full clinical utility has not yet been fully mapped. For patients currently on GLP-1 therapy, this emerging body of evidence provides additional confidence that the medications may be delivering systemic benefits beyond what is visible on the scale.

The approval also accelerates discussions about how obesity itself should be classified and treated within the healthcare system. If a treatment for obesity demonstrably reduces cardiovascular mortality, the longstanding tendency to treat obesity as a cosmetic or behavioral issue — rather than a serious chronic disease — becomes increasingly difficult to sustain from a clinical or policy standpoint.

What Patients Should Do Next

If you have a history of heart attack, stroke, or peripheral artery disease and are living with obesity or overweight, it is worth discussing the SELECT findings and the expanded Wegovy indication with your cardiologist or primary care physician at your next appointment. Bring documentation of your cardiovascular history, your current BMI, and any prior insurance denials for Wegovy or similar medications.

For patients already on Wegovy for weight management, no action is required in terms of the medication itself — the drug and dosing protocol remain the same. However, you may benefit from contacting your insurance provider or working with your prescriber to update your prior authorization or appeal filing to reflect the cardiovascular indication, which may improve coverage prospects.

As with all GLP-1 medications, Wegovy should be used as part of a comprehensive treatment plan that includes dietary changes, physical activity, and behavioral support. The SELECT trial was conducted on top of standard care — meaning the cardiovascular benefits were achieved when semaglutide was combined with, not used in place of, a broader health management approach. Working with a behavioral health professional who understands the GLP-1 treatment landscape can help you sustain the lifestyle changes that amplify the drug's benefits over time.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or modifying any medication or treatment plan. Individual eligibility for Wegovy and insurance coverage decisions vary based on personal medical history, insurer policy, and clinical judgment.